can IMMU-132 affect certain pathways of cancer cells when treating cancers

Yes, IMMU-132 (also known as sacituzumab govitecan) can affect certain pathways of cancer cells when treating cancers. IMMU-132 is an antibody-drug conjugate (ADC) that targets the Trop-2 receptor, which is expressed on the surface of many types of cancer cells.

Once IMMU-132 binds to the Trop-2 receptor, it is internalized into the cancer cell. The drug component of IMMU-132, SN-38, is then released inside the cancer cell, where it inhibits topoisomerase I, an enzyme important for DNA replication and cell division. This inhibition leads to DNA damage and cell death.

Additionally, IMMU-132 has been shown to induce immunogenic cell death, which can stimulate an immune response against the cancer cells. This immune response can further enhance the anti-cancer effects of IMMU-132.

Overall, IMMU-132 can affect multiple pathways involved in cancer cell growth and survival, making it an effective treatment option for certain types of cancers.